论文部分内容阅读
目的观察紫杉醇顺铂化疗方案联合内镜下黏膜剥离术(ESD)治疗食管黏膜病变及胃肠动力学的影响情况。方法 80例食管黏膜病变的患者分为试验组和对照组,每组40例。试验组第1,8,15,22,29,36天静脉滴注紫杉醇400mg·m~(-2)+顺铂20 mg·m~(-2)化疗方案联合ESD,对照组单纯紫杉醇联合顺铂化疗方案。观察2组患者的近期疗效、远期疗效以及不良反应的情况,比较2组患者治疗后肠鸣音、胃肠蠕动、肛门排气、排便功能的恢复时间。结果试验组总有效率为80.00%(32/40),明显高于对照组的67.50%(27/40,P<0.05)。试验组肠鸣音、胃肠蠕动、肛门排气、排便功能的恢复时间为(53.14±3.18),(36.78±9.22),(43.12±10.44),(83.34±4.69)min,均短于对照组(75.21±3.77),(57.28±11.82),(63.82±10.28),(130.55±8.77)min(P<0.05)。试验组总生存率为70.00%(28/40),无进展生存率为60.00%(24/40),局部控制率为57.50%(23/40)均高于对照组的40.00%(16/40),25.00%(10/40),22.50%(9/40)(P<0.05)。2组不良反应发生率差异无统计学意义(P>0.05)。结论紫杉醇顺铂化疗联合ESD治疗食管黏膜病变比单纯的紫杉醇顺铂化疗疗效更好,胃肠动力恢复时间更短,近远期疗效更为显著。
Objective To observe the effect of paclitaxel cisplatin chemotherapy combined with endoscopic mucosal dissection (ESD) on esophageal mucosal lesions and gastrointestinal motility. Methods 80 cases of esophageal mucosal lesions were divided into experimental group and control group, 40 cases in each group. On the first, the eighth, the fifteenth, the twelfth, the twenty-second, the nineteenth and the sixth day in the experimental group, the chemotherapy regimen of paclitaxel 400mg · m -2 and cisplatin 20 mg · m -2 were combined with ESD. Platinum chemotherapy program. The short-term curative effect, long-term curative effect and adverse reactions of the two groups were observed. The recovery time of bowel sounds, gastrointestinal peristalsis, anal exhaust and defecation were compared between the two groups. Results The total effective rate of the experimental group was 80.00% (32/40), which was significantly higher than that of the control group (67.50%, 27/40, P <0.05). The recovery time of bowel sounds, gastrointestinal peristalsis, anal exhaust and defecation in experimental group were (53.14 ± 3.18), (36.78 ± 9.22), (43.12 ± 10.44) and (83.34 ± 4.69) min, respectively, (75.21 ± 3.77), (57.28 ± 11.82), (63.82 ± 10.28), (130.55 ± 8.77) min (P <0.05). The overall survival rate was 70.00% (28/40), the progression-free survival rate was 60.00% (24/40), and the local control rate was 57.50% (23/40) in the experimental group compared with 40.00% in the control group (16/40 ), 25.00% (10/40), 22.50% (9/40) (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Paclitaxel cisplatin combined with ESD treatment of esophageal mucosal lesions than paclitaxel chemotherapy cisplatin better gastrointestinal motility recovery time is shorter, more effective in the short term.